Stock Events

Stock Events

Avecho Biotechnology Limited 

A$0.01
1
+A$0+10% Friday 01:22

Statistics

Day High
0.01
Day Low
0.01
52W High
0.01
52W Low
0
Volume
29,924,548
Avg. Volume
-
Mkt Cap
40.41M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Oct 10
A$0.03
Mar 10
A$0.02
Oct 9
A$0.02
Mar 9
A$0.02
Oct 8
A$0.05
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

29AugExpected
Q2 2022
Q3 2022
Q4 2022
Q2 2023
Q4 2023
Q1 2024
Q2 2024
0
0.33
0.67
1
Expected EPS
N/A
Actual EPS
N/A

Financials

-356.79%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
2.48MRevenue
-8.83MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AVE.AU. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap191.53B
Amgen Inc. is a biotechnology company involved in the development of a wide range of therapeutic products, potentially competing in similar therapeutic areas as Avecho.
Gilead Sciences
GILD
Mkt Cap170.84B
Gilead Sciences, Inc. focuses on the discovery, development, and commercialization of medicines in areas of unmet medical need, overlapping with Avecho's market.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.35B
Regeneron Pharmaceuticals, Inc. is known for its innovation in biopharmaceuticals, directly competing in the biotech pharmaceuticals market.
Vertex Pharmaceuticals
VRTX
Mkt Cap112.22B
Vertex Pharmaceuticals Incorporated operates in the pharmaceuticals sector focusing on serious diseases, similar to Avecho's target market.
Biogen
BIIB
Mkt Cap26.03B
Biogen Inc. develops, markets, and manufactures therapies for neurological and neurodegenerative diseases, competing in overlapping therapeutic areas.
Incyte
INCY
Mkt Cap19.47B
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, similar to Avecho's business model.
Alnylam Pharmaceuticals
ALNY
Mkt Cap41.32B
Alnylam Pharmaceuticals, Inc. is a leader in RNAi therapeutics, competing in the innovative biotech sector alongside Avecho.
Exelixis
EXEL
Mkt Cap11.66B
Exelixis, Inc. is involved in the discovery, development, and commercialization of new medicines with potential overlap in therapeutic areas.
Neurocrine Biosciences
NBIX
Mkt Cap13.4B
Neurocrine Biosciences, Inc. develops treatments for neurological and endocrine-related diseases, potentially competing with Avecho's therapeutic developments.

About

Avecho Biotechnology Limited, a biotechnology company, develops, produces, and sells products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, skin care, animal health, and nutrition industries. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone. The company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. It also provides non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company has a collaboration with Lambert Initiative at the University of Sydney to conduct a study to examine whether topically applied cannabidiol can provide relief from symptoms of osteoarthritis. It serves customers in Australia, Switzerland, India, and internationally. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.
Show more...
CEO
Dr. Paul Gavin BSc (Hons), Ph.D.
Country
Australia
ISIN
AU0000047441

Listings

F
DE
OEZ.F
STU
DE
OEZ.STU
AU
AU
AVE.AU
OTC Link
US
AVEFF

0 Comments

Share your thoughts

FAQ

What is Avecho Biotechnology Limited stock price today?▼
The current price of AVE.AU is A$0.01 AUD — it has increased by +10% in the past 24 hours. Watch Avecho Biotechnology Limited stock price performance more closely on the chart.
What is Avecho Biotechnology Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Avecho Biotechnology Limited stocks are traded under the ticker AVE.AU.
Is Avecho Biotechnology Limited stock price growing?▼
AVE.AU stock has risen by +22.22% compared to the previous week, the month change is a +22.22% rise, over the last year Avecho Biotechnology Limited has showed a +175% increase.
What is Avecho Biotechnology Limited market cap?▼
Today Avecho Biotechnology Limited has the market capitalization of 40.41M
What is Avecho Biotechnology Limited revenue for the last year?▼
Avecho Biotechnology Limited revenue for the last year amounts to 2.48M AUD.
What is Avecho Biotechnology Limited net income for the last year?▼
AVE.AU net income for the last year is -8.83M AUD.
Does Avecho Biotechnology Limited pay dividends?▼
Yes, AVE.AU dividends are paid annual. The last dividend per share was 0.03 AUD. As of today, Dividend Yield (FWD)% is 0%.
In which sector is Avecho Biotechnology Limited located?▼
Avecho Biotechnology Limited operates in the Health & Wellness sector.
When did Avecho Biotechnology Limited complete a stock split?▼
Avecho Biotechnology Limited has not had any recent stock splits.
Where is Avecho Biotechnology Limited headquartered?▼
Avecho Biotechnology Limited is headquartered in Clayton, Australia.